 STOCKHOLM, May 25, 2021 PRNewswire -- Swedish Orphan Biovitrum AB publ SobiTM and Apellis Pharmaceuticals, Inc. Nasdaq: APLS GLOBE NEWSWIRE today reported positive top-line results from the phase 3 PRINCE study evaluating the efficacy and safety of pegcetacoplan in adults with paroxysmal nocturnal haemoglobinuria PNH who are treatment naïve, meaning they had not received a complement inhibitor within three months before entering the study. Pegcetacoplan demonstrated statistical superiority on the co-primary endpoints of haemoglobin stabilization and reduction in lactate dehydrogenase LDH compared to standard of care, which did not include complement inhibitors, at week 26. 